Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

Pancreatic Neoplasms Clinical Trial

Official title:

A Multicenter, One-arm Phase II Clinical Study of Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05795920
• Other study ID #: UTD1-PC-01
• Status: Recruiting
• Phase: Phase 2
• Start date: March 8, 2023
• Est. completion date: September 8, 2025

Study information

• Verified date: March 2023
• Source: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: Qi Li, Prof.
• Phone: +86-13818207333
• Email: leeqi2001[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is an efficacy and safety evaluation of the use of Utidelone injection in combination with gemcitabine for inoperable and locally inappropriate use first-line chemotherapy in the treatment of advanced pancreatic cancer.

Main Purpose:To evaluate the use of utidelone in combination with gemcitabine in unresectable, advanced pancreatic cancer without progressionSurvival (PFS), overall survival (OS), duration of response (DOR), and safety; Secondary objective: Use of utidelone in combination with gemcitabine in patients with unresectable, advanced pancreatic cancer, according to investigators Objective response rates (ORRs) assessed against RECIST v1.1 criteria.

Description:

This trial is a multicenter, single-arm phase II clinical trial of Utidelone (UTD1) injection combined with gemcitabine in patients with unresectable, advanced pancreatic cancer, and the study will include 6 centers and enroll 92 patients.Patients who met the entry criteria received Utidelone in combination with gemcitabine: Utidelone (utidelone ®) injection: 30 mg/m2, administered daily on Days 1-5, in 21-day cycles; gemcitabine: 1000 mg/m2, administered 3 weeks using (Q3W) on Days 1 and 8, in 21-day cycles; treatment period: 6-8 cycles, or until the patient experienced disease progression or intolerable toxicity or death.Tumor assessments will be performed at baseline and every 6 weeks (± 7 days) after enrollment until disease progression according to response evaluation criteria in solid tumours (RECISTv1.1) criteria.For patients without disease progression, tumor assessments will continue regardless of whether or not the patient discontinues study treatment unless consent is withdrawn.Follow-up data collection, including subsequent anticancer therapy, was to occur until patient death, withdrawal of consent, loss to follow-up, or study termination, whichever came first.Safety assessments assessed the incidence, nature, and severity of adverse events and laboratory abnormalities according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 in the Investigator-Initiated Clinical Trial (IIT) Study UTD1-PC-01 14 in Shanghai First People 's Hospital.Laboratory safety assessments included periodic monitoring of hematology and chemistry.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 92
• Est. completion date: September 8, 2025
• Est. primary completion date: July 8, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Patients enrolled in the study must meet all of the following criteria:

1. Age: 18-75 years old.

2. Karnofsky (KPS) physical status score =70.

3. Those confirmed by histopathology or cytology, inoperable and unsuitable for local treatment This is a malignant tumor of pancreatic ductal epithelium, graded as stage ?-? according to the American Joint Committee on Cancer (AJCC) eighth Edition (T4NxM0-1/TxNxM1), except for pancreatic neuroendocrine tumors;

4. Baseline blood routine and biochemical indexes of subjects meet the following standards: hemoglobin =90g/L; neutral Granulocyte absolute count (ANC) =1.5×109g/L; Platelet =100×109/L; glutamine Enzyme (ALT), aspartate aminotransferase (AST) =2.5 times the normal upper limit; Serum total bilirubin <1.5 times the normal upper limit; Serum creatinine <1 times the normal upper limit; Serum albumin

=30g/L.

5. Cardiac function: a) left ventricular ejection fraction (LVEF) =50%; b) 12-ECG showed no myocardial ischemia; c) No history of arrhythmia requiring drug intervention before enrollment;

6. No severe concomitant disease with survival time <5 years, known peripheral nerve disease = grade 1.

7. Agree to and be able to follow the protocol during the study.

8. Provide written informed consent before entering the study screening. -

Exclusion Criteria:

1. For patients with pancreatic cancer who had previously received chemotherapy, radiotherapy or immunotherapy.

2. Patients with pancreatic neuroendocrine tumors confirmed by histopathology or cytology

3. Pregnant or lactating women.

4. Women of childbearing age who had a positive pregnancy test at baseline or did not undergo a pregnancy test. Postmenopausal women must Stop menstruation for at least 12 months before pregnancy is not possible.

5. Men and women who had sex (with the possibility of procreation) were reluctant to use contraception during the study period.

6. Non-melanoma skin cancer and cervical carcinoma in situ were cured in patients with other malignant history in the last 5 years Outside.

7. A history of uncontrolled epilepsy, central nervous system disease or mental disorder, as determined by the investigator Clinical severity can prevent the signing of informed consent or affect patient adherence to oral medication.

8. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association May have grade II or worse congestive heart failure or severe cardiac rhythm requiring medical intervention Disorder, or history of myocardial infarction within the last 12 months.

9. Those who are severely allergic to polyoxyethylene (35) castor oil, or have used anti-microtubule drugs in the past Severe adverse reactions occurred.

10. Known peripheral nerve disease =NCICTC, AE grade 2.

11. severe uncontrolled recurrent infection, or other severe uncontrolled concomitant disease.

12. Moderate or severe renal impairment [creatinine clearance =50ml/min (according to Cockrcoft and Gault equation), or serum creatinine > upper normal limit (ULN) .

13. Acute or chronic active hepatitis B, hepatitis C infection, hepatitis B virus (HBV) DNA > 2000 IU/ml or 104 copies /ml, Hepatitis C virus (HCV) RNA > 103 copies /ml, hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive at the same time, human immunity Epidemic defect virus (HIV).

14. Allergic to Utidelone or gemcitabine.

15. Participants who had received study medication or preparation/treatment (i.e., participating in other trials) within 4 weeks prior to enrollment.

16. Patients who were not eligible to participate in the study for any reason determined by the investigator.

-

Related Conditions & MeSH terms

• Pancreatic Neoplasms

Intervention

Drug:
• Utidelone injection in combination with gemcitabine
Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle

Locations

Country	Name	City	State
China	Shanghai First People's Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	Time from enrollment to death (from any cause)	From date of randomization until the date of death from any cause assessed up to 100 months
Primary	progression free survival progression free survival	Disease progression from baseline assessment of enrollment to first radiographically verifiable disease progression (PD) (RECIST 1.1 standard) or deaths from any cause where progression was not recorded Time.	From date of randomization until the date of first documented progression assessed up to 100 months
Secondary	Duration of response Duration of Response	That is, from the first time the evaluation results meet CR or PR criteria to the observation of PD or death	Time from complete response/partial response (CR/PR) to progression/death (from any cause), assessed up to 100 months